Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2009-08-21
2011-12-13
Huff, Sheela J (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C424S133100
Reexamination Certificate
active
08076093
ABSTRACT:
Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM2. Monoclonal antibodies having the binding characteristics of an MCM2 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM2 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM2 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM2 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.
REFERENCES:
patent: 4281061 (1981-07-01), Zuk et al.
patent: 5858683 (1999-01-01), Keesee et al.
patent: 6303323 (2001-10-01), Laskey et al.
patent: 7056690 (2006-06-01), Laskey et al.
patent: 7157233 (2007-01-01), Fischer et al.
patent: 2002/0106685 (2002-08-01), Henning et al.
patent: 2003/0087270 (2003-05-01), Schlegel et al.
patent: 2003/0219726 (2003-11-01), Doorbar et al.
patent: 2004/0202996 (2004-10-01), Williams et al.
patent: 2005/0250166 (2005-11-01), Masai et al.
patent: 2005/0260566 (2005-11-01), Fischer et al.
patent: 1 388 734 (2004-02-01), None
patent: 1 489 177 (2004-12-01), None
patent: WO 99/21014 (1999-04-01), None
patent: WO 02/101075 (2002-12-01), None
patent: WO 03/065042 (2003-08-01), None
patent: WO 03/076623 (2003-09-01), None
patent: WO 2004/013632 (2004-02-01), None
patent: WO 2005/095964 (2005-10-01), None
Brake, T., et al., “Comparative Analysis of Cervical Cancer in Women and in a Human Papillomavirus-Transgenic Mouse Model: Identification ofMinichromosome Maintenance Protein 7,” Cancer Research, 2003, pp. 8173-8180, vol. 63.
Burgess, S., et al., “Possible Dissociation of the Heparin-Binding and Mitogenic Activities of Heparin-Binding (Acidic Fibroblast) Growth Factor-1 From its Receptor-Binging Activities by Site-Directed Mutagenesis of a Single Lysine Residue,”Journal of Cell Biology, 1990, pp. 2129-2138, vol. 111.
Campbell, “Monoclonal Antibody Technology: The Production and Characterization of Rodent and Human Hybridomas,”Elsevier, 1984, pages 1-32.
Freeman, A., et al., Minichromosome Maintenance Proteins as Biological Markers of Dysplasia and Maliginancy1,Clincal Cancer Research, 1999, pp. 2121-2132, vol. 5.
Going, J.J., et al., Aberrant Expression of Minichromosome Maintenance Proteins 2 and 5, Ki-67 in Dysplastic Squamous Oesophageal Epithelium and Barrett's Mucosa,Cancer, 2006, pp. 373-377, vol. 50.
Krüger, S., et al., Prognostic Value of MCM2 Immunoreactivity in Stage T1 Transitional Cell Carcinoma of the Bladder,European Urology, 2003, pp. 138-145, vol. 43.
Lazar, E., et al., “Transforming Growth Factor A: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,”Molecular and Cellular Biology, 1988, pp. 1247-1252, vol. 8(3).
Lin, M.C. et al., “Structure-Function Relationships Relationships in Glucagon: Properties of Highly Purified Des-His1-Monoiodo-, and [Des-Asn28, Thr29](Homoserine Lactone 27)-Glucagon,”Biochemistry, 1975, pp. 1559-1563, vol. 14(8).
Malinowski, D.P., “Molecular Diagnostic Assays for Cervical Neoplasia: Emerging Markers for the Detection of High-Grade Cervical Disease,”Biotechiques, 2005, pp. 17-23, vol. 38.
Mukherjee, G., et al., “Biologic Factors and Response to Radiotherapy in Carcinoma of the Cervix,”Int. J. Gynecol. Cancer, 2001, pp. 187-193, vol. 11.
Mushika, M. et al., “Detection of Proliferative Cells in Dysplasia, Carcinoma in Situ, and Invasive Carcinoma of the uterine Cervix by Monoclonal Antibody Against DNA Polymerase α,”Cancer, 1998, pp. 1182-1186, vol. 61.
Panka, D.J., et al., “Variable Region Framework Differences Result in Decreased or Increased Affinity of Variant Anti-Digoxin Antibodies,”Proceedings of the National Academy of Sciences, 1988, pp. 3080-3084, vol. 85.
Rudikoff, S., et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity,”Proceedings of the National Academy of Sciences, 1983, pp. 1979-1983, vol. 79.
Schwartz, W., et al., A Superactive Insulin: [B10-Aspartic Acid] Insulin (Human),Proceedings of the National Academy of Sciences, 1987, pp. 6408-6411, vol. 84.
Tan, D.-F., et al., “MCM2-A Promising Marker for Premalignant Lesions of the Lung: A Cohort Study,”BMC Cancer, 2001, pp. 6-12, vol. 1(6).
Product Data Sheet for ab6153, URL: htpp://www.abcam.com/index.html:pageconfig=datasheet&intABID=6153>, Oct. 11, 2000, pp. 1-3.
Product Data Sheet for 17788, URL: htpp://www.abcam.com/index.html?pageconfig=datasheet&intABID=17788>, Mar. 2, 2005, pp. 1-3.
Data Sheet for Minichromosome Maintenance Protein 2, NCL-MCM2, URL:htpp://www.vision-bio.com/pdfs/products/mcm2-u.pdf, Nov. 13, 2006, pp. 1-2.
Baldwin, P., et al. “Translational Approaches to Improving Cervical Screening,”Nature Reviews, Cancer, 2003, pp. 217-226, vol. 3.
Bauman, M.E., et al., “Differential Immunohistochemical Staining for DNA Topoisomerase IIα and β in Human Tissues and for DNA Topoisomerase IIβ in Non-Hodgkin's Lymphomas,” Mod. Pathol. 1997, pp. 168-175, vol. 10, No. 3.
Chatrath, P., et al., “Aberrant Expression of Minichromosome Maintenance Protein-2 and Ki67 in Laryngeal Squamous Epitherlial Lesions,”British Journal of Cancer, 2003, pp. 1048-1054, vol. 89.
Davies, R.J., et al., “Analysis of Minichromosome Maintenance Proteins as a Novel Method for Detection of Colorectal Cancer in Stool,”The Lancet, 2002, pp. 1917-1919, vol. 359(9321).
D'Andrea, M.R., et al., “Immunohistochemical Detection of DNA Topoisomerases IIα and IIβ Compared to Detection of Ki-67, a Marker of Cellular Proliferation, in Human Tumors,” Appl. Immunohistochem. 1994, pp. 177-185, vol. 2, No. 3.
Elit, L.M., “Pitfalls in the Diagnosis of Cervical Intraepithelial Neoplasia 1,”Journal of Lower Genital Tract Disease, 2004, pp. 181-187, vol. 8(3).
Gonzalez, M.A., et al., “Minichromosome Maintenance Protein 2 is a Strong Independent Prognostic Marker in Breast Cancer,”Journal of Clinical Oncology, 2003, pp. 1-8, vol. 21(23).
Hunt, D.P.J., et al., “Early Recurrence of Benign Meningioma Correlates With Expression of Mini-Chromosome Maintenenace-2 Protein,”British Journal of Neurosurgery, 2002, pp. 10-15, vol. 16(1).
Ishimi, Y., et al., “Enhanced Expression of Mcm Proteins in Cancer Cells Derived from Uterine Cervix,”Eur. J Biochem., 2003, pp. 1089-1101, vol. 270.
Laskey, R., “Initiation of DNA Replication in Normal and Neoplastic Cells,”5thCongress of the European Haematology Association—Educational Book, Session 11—Cell Cycle, 2000, pp. 152-155.
Robinson, R.G., et al., “Isolation and Characterization of Monoclonal Antibodies to a Recombinant Human Topoisomerase II Polypeptide,”Hybridoma, 1993, pp. 407-415, vol. 12, No. 4.
Scott, I.S., et al., A Novel Immunohistochemical Method to Estimate Cell-Cycle Phase Distribution in Archival Tissue: Implications for the Prediction of Outcome in Colorectal Cancer,Journal of Pathology, 2003, pp. 187-197, vol. 201.
Todorov, I., et al., “A human nuclear protein with sequence homology to a family of early S phase proteins is required for entry into S phase and for cell division,”Journal of Cell Science, 1994, vol. 107, pp. 253-265.
Whitfield, M.L., “Identification of Genes Periodically Expressed in the Human Cell Cycle and Their Expression in Tumors,”Molecular Biology of the Cell, 2002, pp. 1977-2000, vol. 13.
Williams, G. H., et al., “Improved Cervical Smear Assessment Using Antibodies Against Proteins That Regul
Fischer Timothy J.
Malinowski Douglas P.
Taylor Adriann J.
Alston & Bird LLP
Huff Sheela J
Tripath Imaging, Inc.
LandOfFree
Monoclonal antibodies and methods for their use in the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies and methods for their use in the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies and methods for their use in the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4305089